MASH Care Demands More Than New Drugs: Meena Bansal, MD

Why It Matters

The limited efficacy endpoints and missing outcome data hinder payer adoption and delay broader patient benefit, making biomarker development and cardiovascular safety pivotal for the MASH market’s growth.

Key Takeaways

• Semaglutide and resmetirom are only FDA‑approved MASH drugs as of 2025
• Pipeline includes FXR agonists, ACC inhibitors, tirzepatide, survodutide
• Lack of non‑invasive FDA‑accepted biomarkers hampers trial efficiency
• Cardiovascular outcome data remain a critical unmet need for MASH therapies

Pulse Analysis

Metabolic dysfunction‑associated steatohepatitis (MASH) now affects an estimated 30 million Americans, driving liver‑related morbidity and escalating healthcare costs. The recent FDA approvals of semaglutide and resmetirom mark the first disease‑modifying options, signaling a shift from lifestyle‑only management to pharmacologic intervention. Both drugs demonstrate fibrosis improvement, yet their mechanisms differ—semaglutide leverages GLP‑1 pathways to enhance insulin sensitivity, while resmetirom activates thyroid hormone‑β receptors to reduce hepatic fat accumulation. This dual approval validates the commercial viability of MASH therapeutics and spurs investor confidence.

Beyond the two approved agents, a robust pipeline is emerging, targeting complementary pathways such as bile‑acid signaling (FXR agonists), de‑novo lipogenesis (ACC inhibitors), and dual incretin receptors (tirzepatide, survodutide). These candidates reflect an industry consensus that MASH is a heterogeneous disease requiring personalized treatment based on metabolic phenotype, genetic risk, and gut‑liver axis status. Precision phenotyping—using genomics, metabolomics, and imaging—could match patients to the most effective mechanism, reducing trial failures and accelerating time‑to‑market. However, the absence of FDA‑endorsed non‑invasive biomarkers forces reliance on liver biopsy, inflating study costs and limiting real‑world monitoring.

Regulators and payers are increasingly demanding hard endpoints, particularly reductions in cirrhosis progression and cardiovascular events, to justify reimbursement. Without long‑term outcome data, even promising agents may face pricing pressures and delayed adoption. Consequently, biotech firms are prioritizing integrated trial designs that incorporate cardiovascular safety cohorts and novel imaging biomarkers. Success in these areas will not only close critical evidence gaps but also unlock broader market access, positioning MASH as a flagship indication for next‑generation metabolic therapeutics.